SEI Investments’s Arcutis Biotherapeutics ARQT Stock Holding History

SEI Investments’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.68M	Buy	139,187 +24,934	+22%	+$652K	﹤0.01%	1624
2026 Q2	$3M	Sell	114,253 -91,888	-45%	-$2.14M	﹤0.01%	1757
2026 Q1	$4.86M	Buy	206,141 +101,855	+98%	+$2.6M	﹤0.01%	1552
2025 Q4	$3.03M	Buy	104,286 +78,423	+303%	+$2.01M	﹤0.01%	1649
2025 Q3	$488K	Buy	25,863 +13,764	+114%	+$217K	﹤0.01%	2242
2025 Q2	$170K	Sell	12,099 -27,251	-69%	-$382K	﹤0.01%	2598
2025 Q1	$615K	Buy	+39,350	New	+$554K	﹤0.01%	2076
2023 Q2	–	Sell	-273,599	Closed	-$3.01M	–	2672
2023 Q1	$3.01M	Buy	+273,599	New	+$3.96M	0.01%	1432
2022 Q4	–	Sell	-172,848	Closed	-$3.3M	–	2531
2022 Q3	$3.3M	Buy	172,848 +28,910	+20%	+$655K	0.01%	1294
2022 Q2	$3.07M	Buy	+143,938	New	+$2.95M	0.01%	1349

Other funds holding ARQT

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return

SEI Investments's ARQT Position: Q3 2026 in Review

SEI Investments increased its Arcutis Biotherapeutics (ARQT) stake by 22% in Q3 2026, buying an estimated $652K and bringing the position to 139,187 shares worth $3.68M. The position accounts for ﹤0.01% of the portfolio, ranked #1624.

SEI Investments first reported a position in ARQT in Q2 2022 and has held it in 10 quarters since. The position peaked at $4.86M in Q1 2026. 173 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

SEI Investments held 139,187 shares of Arcutis Biotherapeutics worth $3.68M as of Q3 2026.
SEI Investments bought 24,934 Arcutis Biotherapeutics shares in Q3 2026, an estimated $652K.
Arcutis Biotherapeutics made up ﹤0.01% of SEI Investments's portfolio in Q3 2026, its #1624 holding.
SEI Investments first reported a position in Arcutis Biotherapeutics in Q2 2022 and has held it in 10 quarters since.
SEI Investments's Arcutis Biotherapeutics position peaked at $4.86M in Q1 2026.
173 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on SEI Investments's 13F filing for Q3 2026, filed 10 Nov 2026.